hit counter
ACADIA Pharmaceuticals Inc. (ACAD) Stock News Sentiment & Price - Sentifly
ACAD - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ACADIA Pharmaceuticals Inc. (ACAD)

USA
Biotechnology
NASDAQ
ACAD Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACAD Latest news
Zacks Investment Research
Positive
ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates
2021-11-09 12:14

ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates.

Seeking Alpha
Neutral
ACADIA Pharmaceuticals (ACAD) CEO Stephen Davis on Q3 2021 Results - Earnings Call Transcript
2021-11-08 23:38

ACADIA Pharmaceuticals (ACAD) CEO Stephen Davis on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
2021-11-08 19:09

Acadia (ACAD) delivered earnings and revenue surprises of 66.67% and 3.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
2021-11-08 16:05

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021. “Our third-quarter results reflect volume growth across all channels and our strong relative performance underscores our commercial team's ability to drive sales of NUPLAZID in a challenging environment,” said Steve Davis, Chief Executive Officer. “As we close out the year, we will meet with the FDA to discuss additional analyses supportin

Business Wire
Neutral
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
2021-11-02 09:00

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych Congress 2021, held virtually and in-person October 29-November 1, 2021 in San Antonio, TX. The presentations demonstrate the suboptimal outcomes associated with the off-label use of currently available atypical antipsychotic treatments in managing dementia-related

Business Wire
Neutral
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
2021-11-01 16:05

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously Senior Vice President, Chief Insights and Analytics Officer, will continue to report to Steve Davis, Chief Executive Officer and continue to serve as a member of the company's Executive Management Committee. He will assume responsibility for all sales and mark

Zacks Investment Research
Positive
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2021-10-27 16:11

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire
Neutral
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
2021-10-27 09:00

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 8, 2021, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-8

Zacks Investment Research
Negative
4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes
2021-10-26 11:51

Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.

Forbes
Positive
Neurocrine, ACADIA: Fast Growing Health Care Stocks That Are Underperforming
2021-10-26 09:00

Our theme of Out Of Favor Health Care Stocks includes biotech and pharma names that are seeing a disconnect between their recent financial performance and recent stock price returns. The theme remains down by about 35% year-to-date, compared to the S&P 500 which is up by a solid 21%.

Loading more news...